Research
Hormonal
Participants using the program plus medication were more likely to achieve clinically significant weight loss, with odds ratios ranging from 1.46 to 2.57 for ≥5% weight loss across timepoints.
Integrating a behavioral support app with GLP-1 RA treatment can significantly enhance weight loss outcomes.
StrongSupportsmedium confidence
Participants using the program plus medication were more likely to achieve clinically significant weight loss, with odds ratios ranging from 1.46 to 2.57 for ≥5% weight loss across timepoints (P< .001).
Why this rating
Based on a retrospective observational cohort study with a large sample size.
Source
Digital augmentation of glucagon-like peptide-1 (GLP-1) for obesity management: A retrospective study (Preprint)
Belinda Davey et al. · 2026
DOI 10.2196/preprints.100728
cohort · n=6753
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →